Review paper

Heat shock protein antagonists in early stage clinical trials for NSCLC

Volume: 26, Issue: 5, Pages: 541 - 550
Published: Mar 8, 2017
Abstract
Cancer cells have a higher need of chaperones than normal cells to prevent the toxic effects of intracellular protein misfolding and aggregation. Heat shock proteins (Hsps) belong to these chaperones; they are classified into families according to molecular size. Hsps are upregulated in many cancers and inhibition can inhibit tumor growth by destabilizing proteins necessary for tumor survival. In non-small cell lung cancer (NSCLC), there are...
Paper Details
Title
Heat shock protein antagonists in early stage clinical trials for NSCLC
Published Date
Mar 8, 2017
Volume
26
Issue
5
Pages
541 - 550
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.